Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris - Health News - redOrbit
Links shared publicly online about this topic.
- 450total visits
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris - Health News - redOrbit
LUXEMBOURG, March 10, 2011 /PRNewswire/ -- Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in psoriasis vulgaris. CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology.
View full resource at redorbit.com
Tags: Dermatology, Psoriasis, Biotech, Healthy Living, News, Medical
Most Recently Shared on March 10, 2011 at 11:50 am By:
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris: LUXEMBOURG... http://bit.ly/fon4Bh
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris | wallstreet:online
wallstreet-online.de — “LUXEMBOURG, March 10, 2011 /PRNewswire/ Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, today announced positive results from its Phase IIa study of its lead product CT327 in ...” View full resource at wallstreet-online.de
Most Recently Shared on March 10, 2011 at 9:25 am By:
Creabilis Announces Positive Phase IIa Results for TrkA Kinase Inhibitor CT327 in Psoriasis Vulgaris: LUXEMBOURG... http://bit.ly/eNcxld
Advertisement
